Patents by Inventor Jerome Molette

Jerome Molette has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds for the treatment or alleviation of disorders associated with Tau aggregates
    Patent number: 12202840
    Abstract: The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: January 21, 2025
    Assignee: AC Immune SA
    Inventors: Sreenivasachary Nampally, Emanuele Gabellieri, Jerome Molette, Heiko Kroth, Cedric Boudou
  • Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates
    Patent number: 11814378
    Abstract: The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: November 14, 2023
    Assignee: AC Immune SA
    Inventors: Sreenivasachary Nampally, Emanuele Gabellieri, Jerome Molette
  • Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates
    Publication number: 20230255976
    Abstract: The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).
    Type: Application
    Filed: April 4, 2023
    Publication date: August 17, 2023
    Inventors: Sreenivasachary Nampally, Emanuele Gabellieri, Jerome Molette
  • Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates
    Patent number: 11684625
    Abstract: The present invention relates to novel compounds of formula (I) that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: June 27, 2023
    Assignee: AC Immune SA
    Inventors: Sreenivasachary Nampally, Emanuele Gabellieri, Jerome Molette
  • Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates
    Publication number: 20210267989
    Abstract: The present invention relates to novel compounds of formula (I) that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).
    Type: Application
    Filed: May 30, 2019
    Publication date: September 2, 2021
    Inventors: Sreenivasachary Nampally, Emanuele Gabellieri, Jerome Molette
  • Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates
    Publication number: 20210214371
    Abstract: The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).
    Type: Application
    Filed: May 20, 2019
    Publication date: July 15, 2021
    Inventors: Sreenivasachary Nampally, Emanuele Gabellieri, Jerome Molette, Heiko Kroth, Cedric Boudou
  • AMINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS
    Publication number: 20180273476
    Abstract: The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.
    Type: Application
    Filed: January 22, 2018
    Publication date: September 27, 2018
    Inventors: Andrew Harvey, Agnes Bombrun, Rachel Cooke, Isabelle Jeanclaude-Etter, Nathan Kuchel, Jerome Molette, Jorgen Mould, Dharam Paul, Rajinder Singh, Cristina Donini, Veronique Colovray, Thomas Avery, Julia Crossman, Justin Ripper
  • Amine derivatives as potassium channel blockers
    Patent number: 9914702
    Abstract: The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: March 13, 2018
    Assignees: Bionomics Limited, Merck Patent GmbH
    Inventors: Andrew Harvey, Agnes Bombrun, Rachel Cooke, Isabelle Jeanclaude-Etter, Nathan Kuchel, Jerome Molette, Jorgen Mould, Dharam Paul, Rajinder Singh, Cristina Donini, Veronique Colovray, Thomas Avery, Julia Crossman, Justin Ripper
  • AMINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS
    Publication number: 20170088519
    Abstract: The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.
    Type: Application
    Filed: December 1, 2016
    Publication date: March 30, 2017
    Inventors: Andrew Harvey, Agnes Bombrun, Rachel Cooke, Isabelle Jeanclaude-Etter, Nathan Kuchel, Jerome Molette, Jorgen Mould, Dharam Paul, Rajinder Singh, Cristina Donini, Veronique Colovray, Thomas Avery, Julia Crossman, Justin Ripper
  • Amine derivatives as potassium channel blockers
    Patent number: 9493451
    Abstract: The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: November 15, 2016
    Assignees: Bionomics Limited, Merck Patent GmbH
    Inventors: Andrew Harvey, Agnes Bombrun, Rachel Cooke, Isabelle Jeanclaude-Etter, Nathan Kuchel, Jerome Molette, Jorgen Mould, Dharam Paul, Rajinder Singh, Cristina Donini, Veronique Colovray, Thomas Avery, Julia Crossman, Justin Ripper
  • Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators
    Patent number: 9403835
    Abstract: The present invention provides compounds of Formula (I) as M1 receptor positive allosteric modulators for the treatment of diseases mediated by the muscarinic M1 mediator.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: August 2, 2016
    Assignee: Ares Trading S.A.
    Inventors: Dominique Swinnen, Cyril Montagne, Vincent Pomel, Anna Quattropani, Jerome Molette, Patrick Gerber
  • Amine Derivatives as Potassium Channel Blockers
    Publication number: 20150299184
    Abstract: The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.
    Type: Application
    Filed: March 25, 2015
    Publication date: October 22, 2015
    Inventors: Andrew Harvey, Agnes Bombrun, Rachel Cooke, Isabelle Jeanclaude-Etter, Nathan Kuchel, Jerome Molette, Jorgen Mould, Dharam Paul, Rajinder Singh, Cristina Donini, Veronique Colovray, Thomas Avery, Julia Crossman, Justin Ripper
  • PYRROLIDINES
    Publication number: 20150274657
    Abstract: The invention relates to compounds of formula I: wherein: R is H or alkyl, X denotes one of the following groups: Y is OH, Oalkyl, NR2R3. The compounds are useful e.g. in the treatment of autoimmune and/or inflammatory disorders, such as multiple sclerosis.
    Type: Application
    Filed: September 10, 2013
    Publication date: October 1, 2015
    Applicant: MERCK PATENT GMBH
    Inventors: Cyril Montagne, Jerome Molette, Julie Routier
  • Tetraaza-cyclopenta[a]indenyl and their use as Positive Allosteric Modulators
    Publication number: 20150018343
    Abstract: The present invention provides compounds of Formula (I) as M1 receptor positive allosteric modulators for the treatment of diseases mediated by the muscarinic M1 mediator.
    Type: Application
    Filed: November 30, 2012
    Publication date: January 15, 2015
    Inventors: Dominique Swinnen, Cyril Montagne, Vincent Pomel, Anna Quattropani, Jerome Molette, Patrick Gerber
  • Amine Derivatives as Potassium Channel Blockers
    Publication number: 20140336198
    Abstract: The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.
    Type: Application
    Filed: May 16, 2012
    Publication date: November 13, 2014
    Applicants: MERCK PATENT GMBH, BIONOMICS LIMITED
    Inventors: Andrew Harvey, Agnes Bombrun, Rachel Cooke, Isabelle Jeanclaude-Etter, Nathan Kuchel, Jerome Molette, Jorgen Mould, Dharam Paul, Rajinder Singh, Cristina Donini, Veronique Colovray, Thomas Avery, Julia Crossman, Justin Ripper